文献速递泌尿生殖MR

表观扩散系数值在鉴别前列腺PI-RADS v2.1 1类「结节中结节」良恶性病变中的诊断效能

Diagnostic performance of apparent diffusion coefficient values in differentiating benign from malignant lesions in prostate PI-RADS v2.1 category 1 "nodules in nodule".
PubMed 文献 · Abdom Radiol (NY) · 2025-04-28

回顾性分析226例男性患者前列腺MRI后活检图像,评估PI-RADS v2.1 1类「结节中结节」的ADC值与病理特征的关系。病理证实为临床显著前列腺癌的结节ADC值低于良性前列腺增生,移行带AUC为0.799(截断值0.835×10⁻³mm²/s),外周带AUC为0.873(截断值0.795×10⁻³mm²/s)。作者认为移行带ADC值低于0.835×10⁻³mm²/s时可将该结节PI-RADS v2.1评分升级为3分。

要点

  • PI-RADS v2.1 1类「结节中结节」中,病理证实为临床显著前列腺癌者ADC值低于良性前列腺增生。
  • 移行带ADC截断值0.835×10⁻³mm²/s时AUC为0.799,外周带截断值0.795×10⁻³mm²/s时AUC为0.873。
  • 作者认为移行带ADC值小于0.835×10⁻³mm²/s时可将该结节PI-RADS v2.1评分升级为3分。

核心结论

  • 在PI-RADS v2.1 1类「结节中结节」患者中,移行带ADC值小于0.835×10⁻³mm²/s时可将该结节的PI-RADS v2.1评分升级为3分。

研究设计与样本

  • 回顾性分析2019年1月至2024年12月接受MRI后活检的226例男性患者前列腺图像。
  • 由两名放射科医师以双盲方式评估检出结节的PI-RADS v2.1分类并测量前列腺结节ADC值。
  • 采用独立样本t检验或Mann-Whitney U检验分析ADC值与结节病理特征的关系。

关键影像表现/征象

  • PI-RADS v2.1 1类「结节中结节」病理证实为临床显著前列腺癌的ADC值低于良性前列腺增生(移行带:0.739±0.15 vs 0.984±0.24,单位×10⁻³mm²/s;外周带:0.719±0.17 vs 1.036±0.21,单位×10⁻³mm²/s,p<0.001)。

诊断标准与关键数值

  • 移行带ADC值诊断临床显著前列腺癌的AUC为0.799,截断值为0.835×10⁻³mm²/s。
  • 外周带ADC值诊断临床显著前列腺癌的AUC为0.873,截断值为0.795×10⁻³mm²/s。
  • 病理证实为临床显著前列腺癌与良性前列腺增生患者间总前列腺特异性抗原、游离/总PSA、PSA密度及前列腺体积差异均有统计学意义(均p<0.05)。

临床应用与阅片要点

  • 作者认为,PI-RADS v2.1 1类「结节中结节」患者中,移行带ADC值小于0.835×10⁻³mm²/s时可将该结节PI-RADS v2.1评分升级为3分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To explore the associations between the apparent diffusion coefficient (ADC) values of prostate PI-RADS v2.1 category 1 "nodules in nodule" and their pathological characteristics.

METHODS: We retrospectively analyzed the prostate images from 226 male patients who underwent biopsy following MRI from January 2019 to December 2024. Two radiologists evaluated the PI-RADS v2.1 categories of identified nodules, measured the ADC values of the prostate nodules in a double-blind manner, and analyzed the associations between these values and the pathological characteristics of the nodules via independent sample t tests or Mann-Whitney U test.

RESULTS: The ADC values of PI-RADS v2.1 category 1 "nodules in nodule" pathologically confirmed as clinically significant prostate cancer (csPCa) were lower than those of benign prostate hyperplasia (BPH) ((unit in ×10- 3 mm2/s)TZ: 0.739 ± 0.15 versus 0.984 ± 0.24; PZ: 0.719 ± 0.17 versus 1.036 ± 0.21, p < 0.001). The AUCs were 0.799 (TZ) with a cutoff of 0.835 × 10- 3mm2/s, and 0.873(PZ) with a cutoff of 0.795 × 10- 3mm2/s, respectively. The total prostate-specific antigen (tPSA), free/t PSA, PSA density (PSAD), and prostate gland volume (PGV) differed significantly between patients with PI-RADS v2.1 "nodules in nodule" that were pathologically confirmed as csPCa and patients with BPH (all p < 0.05).

CONCLUSION: In patients with PI-RADS v2.1 category 1 "nodules in nodule", when the ADC values are less than 0.835 × 10- 3mm2/s in the TZ, the PI-RADS v2.1 score of the nodule can be upgraded to 3.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Sun M, Li F, Zhang X, et al. Diagnostic performance of apparent diffusion coefficient values in differentiating benign from malignant lesions in prostate PI-RADS v2.1 category 1 "nodules in nodule". Abdom Radiol (NY). 2025. PMID: 40293519. doi:10.1007/s00261-025-04930-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。